Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
S-8
Share Issue/Capital Change Classification · 85% confidence The document is a Securities and Exchange Commission Form S-8 (“Registration Statement under the Securities Act of 1933”) filed by Enveric Biosciences to register additional shares of common stock for issuance under its 2020 Long-Term Incentive Plan. A Form S-8 is not an earnings release, annual report, proxy statement, or management discussion; rather it formalizes the issuance of new shares under an employee plan. This falls squarely under “Share Issue/Capital Change” (SHA) in our taxonomy, which covers announcements and filings relating to new share issues or other capital structure changes.
2026-05-29 English
8-K
Regulatory Filings
2026-05-29 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K
Regulatory Filings Classification · 87% confidence The provided text is a Form 8-K Current Report filed with the SEC (Section 13 or 15(d) of the Exchange Act). It does not contain substantive financial statements itself but instead furnishes a press release as Exhibit 99.1 announcing Q1 results. As a standalone SEC Form 8-K (a regulatory filing), it best fits the “Regulatory Filings (RNS)” category rather than an actual earnings release or full report.
2026-05-15 English
Regulatory Filings 2026
Regulatory Filings
2026-05-04 English
8-K
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K “Current Report” under Item 8.01 “Other Events” describing the filing of a definitive proxy statement on Schedule 14A and subsequent additional proxy materials to correct typographical errors. It does not itself contain the full proxy statement content, but merely announces and references the filing of the report and additional materials (Exhibit 99.1). Under our taxonomy, this fits “Report Publication Announcement (RPA)” because it is an announcement of the timing and publication of company reports rather than the report content itself.
2026-04-30 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.